Texray develops cutting-edge radiation protection solutions for healthcare professionals facing high radiation exposure during x-ray-guided surgical procedures. Current protection gear often leaves vulnerable areas exposed, increasing the risk of radiation-related health issues. Texray’s groundbreaking technology provides the highest level of protection while prioritizing the comfort of OR/Cathlab staff. With CE/FDA registrations and several global regulatory approvals, Texray is revolutionizing Personal Protective Equipment (PPE) in key markets, addressing a critical gap in radiation protection.

Petra Apell, CEO of Texray, commented: “We are thrilled by the immense support we have received from investors who would like to join us on our journey when we aim to become one of the world’s leading companies in radiation protection. This investment will enable us to accelerate commercialization and to further our mission in advancing occupational safety for healthcare professionals with our cutting-edge technology.”

Texray currently offers two regulatory-approved products in its portfolio, used by over 1000 customers. This trust is further supported by strong endorsements from numerous key opinion leaders within the medical community. As Texray stands on the cusp of a broader market launch, the company’s dedication to revolutionizing radiation protection has never been more evident.

Tobias Elmquist, Senior Investment Director at Industrifonden, commented: “There is a growing awareness of the risks associated with radiation exposure among healthcare professionals, and Texray stands as the sole provider of a radiation protection textile that combines optimal shielding with a comfortable design, setting new industry standards for safety and comfort. Their technology represents a critical leap forward in safeguarding the lives of those who dedicate themselves to the well-being of others. We believe in the Texray mission and are excited to be part of their journey.”